Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Capital Expenditures (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Capital Expenditures for 11 consecutive years, with $59000.0 as the latest value for Q1 2026.

  • For Q1 2026, Capital Expenditures fell 88.97% year-over-year to $59000.0; the TTM value through Mar 2026 reached $5.0 million, down 48.3%, while the annual FY2025 figure was $5.5 million, 40.02% down from the prior year.
  • Capital Expenditures hit $59000.0 in Q1 2026 for Cartesian Therapeutics, down from $492000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $6.2 million in Q3 2024 and bottomed at -$77000.0 in Q3 2023.
  • Average Capital Expenditures over 5 years is $995937.5, with a median of $323500.0 recorded in 2022.
  • Year-over-year, Capital Expenditures tumbled 117.66% in 2023 and then surged 18141.67% in 2024.
  • Cartesian Therapeutics' Capital Expenditures stood at $211000.0 in 2022, then plummeted by 70.14% to $63000.0 in 2023, then soared by 1019.05% to $705000.0 in 2024, then tumbled by 30.21% to $492000.0 in 2025, then tumbled by 88.01% to $59000.0 in 2026.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $59000.0, $492000.0, and $4.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.